Member Info for ciaskin

Sath is going...

https://twitter.com/scancellpharma/status/1743284985954496975?t=IyL9XtmHyUlF9SfJTlscrg&s=19

Eisai ranked #38 in the world (pharmaexec.com) with $4.6 billion in annual sales and $1.2 billion in R&D spend (2022). So yes, a pretty decent sized partner...

Another good thing to come out of the AGM was Lindy confirming that iSCIB1+ will extend patent life to 2039 (as per July 10th RNS) rather than 2031 (as per Oct 31st RNS) which she said had been "a typo". However, given that this was price-sensitive information (and in this case, a potentially price-damaging mistake) should there not have been an RNS retraction/correction immediately?

Another good thing to come out of the AGM was Lindy confirming that iSCIB1+ will extend patent life to 2039 (as per July 10th RNS) rather than 2031 (as per Oct 31st RNS) which she said had been "a typo". However, given that this was price-sensitive information (and in this case, a potentially price-damaging mistake) should there not have been an RNS retraction/correction immediately?

We'll spotted, Cleaner. Good coverage and it'll be interesting so see if the Mail runs with this in business/personal finance pages over the weekend...

Forbes, no less!! Great find and great PR!

I think she used it in the context of trial leads, clinicians and the like. In other words, when people like Christian Ottensmeier, Poulam Patel and so on start seeing first hand what Scib can do, they spread the word and effectively, they lead clinical opinion. If these key opinion leaders are impressed, then it must be really good, is the thinking, other oncologists start taking note and hopefully, so does Big Pharma!

KOLs = Key Opinion Leaders

Snap!

Resolutions are always the first items on the agenda of an AGM so Consilium have just been quick off the mark on that bit of regulatory requirement. Meeting still going on I would expect...

Complete response! You little beauty...

Agreed Torquay. I posted purely for context and balance but good to see that some people are questioning the merits of personalised medicines as being the only way forward...

For the benefit of occasional BB readers, let me put the 'RIP personalised medicines' claim into context. This was simply the conclusion of one speaker in a 'this house believes...' debate. The other side, by definition, believes the opposite to be true. See slide below.

https://twitter.com/livHeadandNeck/status/1725543598177837348?t=lrCGNacG1MX1ORuqfq67CA&s=19

Research note from Turner Pope:

https://mailchi.mp/turnerpope.com/ironveld-plc-research-note-11214099?e=ba1847ebf6

Yes Mia. Not "was doing very well" or "has been doing very well" but "IS doing very well."

Telling methinks...

I'd be happy to. Three weeks on and I'm still waiting for even an acknowledgement of my emails and calls to Consilium about the patent expiry dates. Peas poor.

Thanks for the tip Berm. I'll try via the SCLP contact page and see if I get an answer. After all, patent expiry dates are rather important...

Was that Consilium you emailed? If so, and if my experience is anything to go by, you'll be waiting a very, very long time before they reply - if at all.

Hi Burble. I'd normally suggest contacting Consilium for clarification but I am still waiting for even an acknowledgement of several emails and calls on the patent expiry date confusion caused by the last RNS. Why do they even bother putting their contact details on an RNS if they are not going to respond??

Of the five patients that had reached the week 19 imaging timepoint, all five patients showed a sustained reduction in the overall tumour burden and this durability of response was also seen

in four patients reaching week 25 and two reaching week 37 imaging timepoints. In the two patients that had reached week 37

the shrinkage was between -87 and -94%. The responders at week 13 are ongoing with their study treatment and will be observed for

the total study period of 2 years.

Reassuringly, the addition of the SCIB1 to the standard of care Ipilimumab with nivolumab did not enhance the toxicity of the Checkpoint combination therapy in the patients evaluated to date.